National Pension Service Increases Holdings in ResMed Inc. (NYSE:RMD)

National Pension Service raised its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 5.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 227,655 shares of the medical equipment provider's stock after purchasing an additional 10,880 shares during the period. National Pension Service owned 0.16% of ResMed worth $55,575,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. OFI Invest Asset Management bought a new position in shares of ResMed during the 2nd quarter valued at approximately $32,000. Versant Capital Management Inc boosted its position in shares of ResMed by 196.7% in the second quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 120 shares during the period. Financial Connections Group Inc. purchased a new stake in shares of ResMed in the second quarter worth $37,000. Blue Trust Inc. raised its position in shares of ResMed by 182.7% during the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 137 shares during the period. Finally, Rothschild Investment LLC purchased a new position in shares of ResMed during the 2nd quarter valued at $44,000. Hedge funds and other institutional investors own 54.98% of the company's stock.

Insider Activity

In related news, CFO Brett Sandercock sold 1,000 shares of ResMed stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $212.16, for a total transaction of $212,160.00. Following the completion of the transaction, the chief financial officer now directly owns 89,056 shares of the company's stock, valued at approximately $18,894,120.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other ResMed news, General Counsel Michael J. Rider sold 882 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $231.00, for a total value of $203,742.00. Following the sale, the general counsel now owns 10,512 shares in the company, valued at $2,428,272. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Brett Sandercock sold 1,000 shares of the business's stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $212.16, for a total transaction of $212,160.00. Following the sale, the chief financial officer now directly owns 89,056 shares of the company's stock, valued at $18,894,120.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,260 shares of company stock valued at $14,602,647. 0.71% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. KeyCorp raised their price target on ResMed from $251.00 to $266.00 and gave the company an "overweight" rating in a report on Friday, October 25th. StockNews.com raised ResMed from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. Needham & Company LLC restated a "hold" rating on shares of ResMed in a research note on Friday, October 25th. Wolfe Research reiterated an "underperform" rating and set a $180.00 price objective on shares of ResMed in a research report on Wednesday, September 18th. Finally, Royal Bank of Canada upped their target price on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a research report on Friday, October 25th. One analyst has rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $225.70.

ResMed Price Performance

Shares of NYSE RMD traded down $0.11 during mid-day trading on Wednesday, hitting $245.63. 789,821 shares of the company's stock traded hands, compared to its average volume of 1,052,595. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. ResMed Inc. has a 1 year low of $140.81 and a 1 year high of $260.49. The company's 50-day moving average is $243.12 and its two-hundred day moving average is $221.39. The company has a market capitalization of $36.06 billion, a P/E ratio of 32.53, a PEG ratio of 1.78 and a beta of 0.69.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.03 by $0.17. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company's quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.64 earnings per share. On average, equities analysts anticipate that ResMed Inc. will post 9.22 EPS for the current fiscal year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Thursday, November 7th. ResMed's dividend payout ratio (DPR) is 28.08%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.